Araştırma Makalesi
BibTex RIS Kaynak Göster

Outcomes and predictors of malignancy in radiologically non-adenomatous adrenal lesions: a retrospective study

Yıl 2025, Cilt: 6 Sayı: 4, 377 - 382, 31.08.2025
https://doi.org/10.47582/jompac.1744560

Öz

Aims: To compare the clinical, radiological, functional, and pathological characteristics of radiologically diagnosed adrenal adenomas versus non-adenomatous lesions and to identify predictors of malignancy and clinical significance among the nonadenomatous group.
Methods: This retrospective study included 63 adult patients who underwent adrenalectomy between January 2015 and December 2024. Patients were classified based on preoperative computed tomography (CT) and/or magnetic resonance imaging (MRI) reports as having either radiologically suspected adrenal adenoma or non-adenomatous lesions. Clinical features, comorbidities, hormonal function, imaging characteristics, and histopathological outcomes were compared between the two groups. Logistic regression analysis was performed within the non-adenomatous group to identify independent predictors of malignancy and clinical relevance. ROC curve analysis was used to assess the diagnostic utility of tumor size.
Results: Of the 63 patients, 29 (46.0%) were classified as adrenal adenomas and 34 (54.0%) as non-adenomatous lesions. Tumor size was significantly smaller in the adenoma group (mean 27.1±6.8 mm vs. 48.5±13.7 mm, p<0.001). Functional tumors were more prevalent in the adenoma group (93.1% vs. 41.2%, p<0.001). Malignancy (adrenocortical carcinoma and metastasis) was observed exclusively in the non-adenomatous group. Within this group, functional lesions were independently associated with malignancy (p=0.019, OR=8.95). ROC analysis showed moderate diagnostic value of tumor size for predicting malignancy (AUC=0.648, 95% CI: 0.372–0.924). Histopathological confirmation showed perfect concordance in the adenoma group (positive predictive value 100%). The adenoma group had higher rates of hypertension (p=0.013) and coronary artery disease (p=0.012).
Conclusion: Radiologically non-adenomatous adrenal lesions are more likely to be malignant than radiologically diagnosed adenomas. Tumor size and functional status can aid in malignancy prediction within this subgroup. Radiologic classification offers high specificity, particularly for adenomas, and may guide preoperative risk stratification.

Etik Beyan

DISCLOSURE OF ETHICAL STATEMENTS • Approval of the research protocol: Approved by the Ethics Committee of Tokat Gaziosmanpasa University (approval date: June 10, 2025; decision number: 24-MOBAEK-211). • Informed Consent: N/A (due to retrospective study design). • Approval date of Registry and the Registration No. of the study/trial: N/A (not a registered clinical trial). • Financial Disclosure: The authors declared that this study has received no financial support. • Conflict of interest: The authors declare no conflicts of interest. • Author Contributions: : All of the authors declare that they have all participated in design, execution, and analysis of the paper and that they have approved the final version

Destekleyen Kurum

• Financial Disclosure: The authors declared that this study has received no financial support.

Kaynakça

  • Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610. doi:10.1056/NEJMcp065470
  • Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009; 161(4):513-527. doi:10.1530/EJE-09-0234
  • Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi:10.1530/EJE-16-0467
  • Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: 10.1111/joim.12831
  • Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019;171(2):107-116. doi:10.7326/M18-3630
  • Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(6):1163-1168. doi:10.2214/AJR.07.2799
  • Lanoix J, Djelouah M, Chocardelle L, et al. Differentiation between heterogeneous adrenal adenoma and non-adenoma adrenal lesion with CT and MRI. Abdom Radiol (NY). 2022;47(4):1379-1391. doi:10.1007/s00261-022-03409-4
  • Bancos I, Tamhane S, Shah M, et al. The diagnostic performance of adrenal imaging in predicting malignancy: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(4):R153-R165. doi:10.1530/EJE-16-0335
  • Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology. 2008;249(3):756-775. doi:10.1148/radiol. 2493070976
  • Duan F, Cui L, Wang Y, Liu G, Wang Y, Liu Z. Comparison of diagnostic accuracy of CT and MRI in adrenal lesions: a meta-analysis. Clin Radiol. 2012;67(1):56-61. doi:10.1016/j.crad.2011.06.020
  • Torresan F, Crimì F, Ceccato F, et al. Radiomics: a new tool to differentiate adrenocortical adenoma from carcinoma. BJS Open. 2021;5(1):zraa061. doi:10.1093/bjsopen/zraa061
  • Albano D, Agnello F, Midiri F, et al. Imaging features of adrenal masses. Insights Imaging. 2019;10(1):1. doi:10.1186/s13244-019-0688-8
  • Magennis DP, McNicol AM. Vascular patterns in the normal and pathological human adrenal cortex. Virchows Arch. 1998;433(1):69-73. doi:10.1007/s004280050218
  • Desai K, Pereira K, Iqbal S, et al. THU602 A comprehensive review of incidence, demographics, laterality and survival analysis of adrenal malignancies. J Endocr Soc. 2023;7(Suppl 1):bvad114.132. doi:10.1210/jendso/bvad114.132
  • Foo E, Turner R, Wang KC, et al. Predicting malignancy in adrenal incidentaloma and evaluation of a novel risk stratification algorithm. ANZ J Surg. 2018;88(3):E173-E177. doi:10.1111/ans.13868
  • Mínguez Ojeda C, Gómez Dos Santos V, Álvaro Lorca J, et al. Tumour size in adrenal tumours: its importance in the indication of adrenalectomy and in surgical outcomes—a single-centre experience. J Endocrinol Invest. 2022;45(10):1999-2006. doi:10.1007/s40618-022-01836-0
  • Pantalone KM, Gopan T, Remer EM, et al. Change in adrenal mass size as a predictor of a malignant tumor. Endocr Pract. 2010;16(4):577-587. doi:10.4158/EP09351.OR
  • Gargan ML, Lee E, O'Sullivan M, et al. Imaging features of atypical adrenocortical adenomas: a radiological-pathological correlation. Br J Radiol. 2022;95(1129):20210642. doi:10.1259/bjr.20210642
  • Nasiroğlu Imga N, Aslan Y, Çatak M, et al. Clinical, radiological, and surgical outcomes of 431 patients with adrenal incidentalomas: retrospective study of a 10-year single-center experience. Turk J Med Sci. 2024;54(2):376-383. doi:10.55730/1300-0144.5802
  • Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5): 1889-1916. doi:10.1210/jc.2015-4061
  • Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-2300. doi:10.1016/j.jacc.2006.07.059
  • Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2(5):396-405. doi:10.1016/S2213-8587(13)70211-0

Radyolojik olarak adenom dışı değerlendirilen adrenal lezyonlarda malignite sonuçları ve öngördürücü faktörler

Yıl 2025, Cilt: 6 Sayı: 4, 377 - 382, 31.08.2025
https://doi.org/10.47582/jompac.1744560

Öz

Amaç:
Radyolojik olarak adenom tanısı almış adrenal lezyonlar ile adenom dışı lezyonların klinik, radyolojik, fonksiyonel ve patolojik özelliklerini karşılaştırmak; ayrıca adenom dışı grupta malignite ve klinik olarak anlamlı lezyonları öngören faktörleri belirlemektir.
Yöntemler:
Bu retrospektif çalışmaya Ocak 2015 ile Aralık 2024 tarihleri arasında adrenalektomi uygulanmış 63 erişkin hasta dahil edilmiştir. Hastalar, preoperatif BT ve/veya MR raporlarına göre radyolojik olarak adenom veya adenom dışı adrenal lezyonlar şeklinde sınıflandırılmıştır. Klinik özellikler, eşlik eden hastalıklar, hormonal fonksiyon, görüntüleme bulguları ve histopatolojik sonuçlar iki grup arasında karşılaştırılmıştır. Adenom dışı grupta malignite ve klinik olarak anlamlı lezyonları öngören bağımsız faktörleri belirlemek için lojistik regresyon analizi uygulanmıştır. Tümör boyutunun tanısal değerini değerlendirmek amacıyla ROC eğrisi analizi yapılmıştır.
Bulgular:
Toplam 63 hastanın 29’u (%46.0) adenom, 34’ü (%54.0) adenom dışı lezyon olarak sınıflandırılmıştır. Tümör boyutu adenom grubunda anlamlı derecede daha küçüktür (ortalama 27.1 ± 6.8 mm vs. 48.5 ± 13.7 mm, p<0.001). Fonksiyonel tümörler adenom grubunda daha sık görülmüştür (%93.1 vs. %41.2, p<0.001). Malignite (adrenokortikal karsinom ve metastaz) yalnızca adenom dışı grupta saptanmıştır. Bu grup içinde, fonksiyonel lezyonlar malignite ile bağımsız olarak ilişkili bulunmuştur (p=0.019, OR=8.95). ROC analizi, tümör boyutunun maligniteyi öngörmede orta düzeyde tanısal değere sahip olduğunu göstermiştir (AUC=0.648, %95 GA: 0.372–0.924). Adenom grubunda histopatolojik doğrulama tam uyum göstermiştir (pozitif prediktif değer %100). Hipertansiyon (p=0.013) ve koroner arter hastalığı (p=0.012) adenom grubunda daha yüksek oranlarda gözlenmiştir.
Sonuç:
Radyolojik olarak adenom dışı değerlendirilen adrenal lezyonlar, adenomlara kıyasla malignite açısından daha yüksek risk taşımaktadır. Bu grupta tümör boyutu ve fonksiyonel durum, malignite öngörüsünde yardımcı olabilir. Radyolojik sınıflama, özellikle adenomlar için yüksek özgüllük sunmakta olup preoperatif risk sınıflandırmasında yol gösterici olabilir.

Kaynakça

  • Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610. doi:10.1056/NEJMcp065470
  • Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009; 161(4):513-527. doi:10.1530/EJE-09-0234
  • Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi:10.1530/EJE-16-0467
  • Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: 10.1111/joim.12831
  • Elhassan YS, Alahdab F, Prete A, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019;171(2):107-116. doi:10.7326/M18-3630
  • Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(6):1163-1168. doi:10.2214/AJR.07.2799
  • Lanoix J, Djelouah M, Chocardelle L, et al. Differentiation between heterogeneous adrenal adenoma and non-adenoma adrenal lesion with CT and MRI. Abdom Radiol (NY). 2022;47(4):1379-1391. doi:10.1007/s00261-022-03409-4
  • Bancos I, Tamhane S, Shah M, et al. The diagnostic performance of adrenal imaging in predicting malignancy: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(4):R153-R165. doi:10.1530/EJE-16-0335
  • Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology. 2008;249(3):756-775. doi:10.1148/radiol. 2493070976
  • Duan F, Cui L, Wang Y, Liu G, Wang Y, Liu Z. Comparison of diagnostic accuracy of CT and MRI in adrenal lesions: a meta-analysis. Clin Radiol. 2012;67(1):56-61. doi:10.1016/j.crad.2011.06.020
  • Torresan F, Crimì F, Ceccato F, et al. Radiomics: a new tool to differentiate adrenocortical adenoma from carcinoma. BJS Open. 2021;5(1):zraa061. doi:10.1093/bjsopen/zraa061
  • Albano D, Agnello F, Midiri F, et al. Imaging features of adrenal masses. Insights Imaging. 2019;10(1):1. doi:10.1186/s13244-019-0688-8
  • Magennis DP, McNicol AM. Vascular patterns in the normal and pathological human adrenal cortex. Virchows Arch. 1998;433(1):69-73. doi:10.1007/s004280050218
  • Desai K, Pereira K, Iqbal S, et al. THU602 A comprehensive review of incidence, demographics, laterality and survival analysis of adrenal malignancies. J Endocr Soc. 2023;7(Suppl 1):bvad114.132. doi:10.1210/jendso/bvad114.132
  • Foo E, Turner R, Wang KC, et al. Predicting malignancy in adrenal incidentaloma and evaluation of a novel risk stratification algorithm. ANZ J Surg. 2018;88(3):E173-E177. doi:10.1111/ans.13868
  • Mínguez Ojeda C, Gómez Dos Santos V, Álvaro Lorca J, et al. Tumour size in adrenal tumours: its importance in the indication of adrenalectomy and in surgical outcomes—a single-centre experience. J Endocrinol Invest. 2022;45(10):1999-2006. doi:10.1007/s40618-022-01836-0
  • Pantalone KM, Gopan T, Remer EM, et al. Change in adrenal mass size as a predictor of a malignant tumor. Endocr Pract. 2010;16(4):577-587. doi:10.4158/EP09351.OR
  • Gargan ML, Lee E, O'Sullivan M, et al. Imaging features of atypical adrenocortical adenomas: a radiological-pathological correlation. Br J Radiol. 2022;95(1129):20210642. doi:10.1259/bjr.20210642
  • Nasiroğlu Imga N, Aslan Y, Çatak M, et al. Clinical, radiological, and surgical outcomes of 431 patients with adrenal incidentalomas: retrospective study of a 10-year single-center experience. Turk J Med Sci. 2024;54(2):376-383. doi:10.55730/1300-0144.5802
  • Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5): 1889-1916. doi:10.1210/jc.2015-4061
  • Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-2300. doi:10.1016/j.jacc.2006.07.059
  • Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2(5):396-405. doi:10.1016/S2213-8587(13)70211-0
Toplam 22 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Endokrinoloji
Bölüm Research Articles [en] Araştırma Makaleleri [tr]
Yazarlar

Merve Çatak 0000-0003-2654-3911

Bülent Koca 0000-0001-7614-122X

Erken Görünüm Tarihi 30 Ağustos 2025
Yayımlanma Tarihi 31 Ağustos 2025
Gönderilme Tarihi 17 Temmuz 2025
Kabul Tarihi 2 Ağustos 2025
Yayımlandığı Sayı Yıl 2025 Cilt: 6 Sayı: 4

Kaynak Göster

AMA Çatak M, Koca B. Outcomes and predictors of malignancy in radiologically non-adenomatous adrenal lesions: a retrospective study. J Med Palliat Care / JOMPAC / Jompac. Ağustos 2025;6(4):377-382. doi:10.47582/jompac.1744560

images?q=tbn:ANd9GcRrI_RWgGRe7JRpz3PAnkt2YEFD2l6WEmgHMzuM2w9b&s

f9ab67f.png     

7yziemq.png




COPE.jpg

icmje_1_orig.png

cc.logo.large.png

ncbi.png

ORCID_logo.png

images?q=tbn:ANd9GcQk2AsOdjP67NBkYAqd8FHwCmh0_3dkMrXh3mFtfPKXwIai7h0lIds8QYM9YjKMhZw8iP0&usqp=CAU

logo_world_of_journals_no_margin.png1280px-WorldCat_logo.svg.png                             images?q=tbn:ANd9GcRrI_RWgGRe7JRpz3PAnkt2YEFD2l6WEmgHMzuM2w9b&s


Dergimiz; TR-Dizin ULAKBİM, ICI World of  Journal's, Index Copernicus, Directory of Research Journals Indexing (DRJI), General Impact Factor, Google Scholar, Researchgate, WorldCat (OCLC), CrossRef (DOI), ROAD, ASOS İndeks, Türk Medline İndeks, Eurasian Scientific Journal Index (ESJI) ve Türkiye Atıf Dizini'nde indekslenmektedir.

EBSCO, DOAJ, OAJI, ProQuest dizinlerine müracaat yapılmış olup, değerlendirme aşamasındadır.

Makaleler "Çift-Kör Hakem Değerlendirmesi”nden geçmektedir.

Üniversitelerarası Kurul (ÜAK) Eşdeğerliği: Ulakbim TR Dizin'de olan dergilerde yayımlanan makale [10 PUAN] ve 1a, b, c hariç uluslararası indekslerde (1d) olan dergilerde yayımlanan makale [5 PUAN].

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser.  About predatory/questionable journals and journal charge policy

Not: Dergimiz WOS indeksli değildir ve bu nedenle Q  sınıflamasına dahil değildir.
Yağmacı/şüpheli dergilerle ilgili Yüksek Öğretim Kurumu (YÖK) kararları ve yazar açıklama metni ile dergi ücret politikası: Yağmacı/Şaibeli Dergiler ve Dergi Ücret Politikası